Table 1 Demographic characteristics of the study population stratified by kidney replacement therapy.

From: Characteristics of fracture in patients who firstly starts kidney replacement therapy in Korea: a retrospective population-based study

Characteristics

Overall (n = 52,777)

HD (n = 45,619)

KT (n = 3305)

PD (n = 3853)

Observation duration, mean (SD), years

4.50 (2.49)

4.48 (2.52)

4.51 (2.34)

4.66 (2.35)

Age at index date, mean (SD), years

59.21 (14.19)

60.78 (13.69)

44.62 (11.62)

53.16 (13.25)

18–29, n (%)

1335 (2.53)

794 (1.74)

385 (11.65)

156 (4.05)

30–39, n (%)

3695 (7.00)

2526 (5.54)

738 (22.33)

431 (11.19)

40–49, n (%)

8191 (15.52)

6311 (13.83)

943 (28.53)

937 (24.32)

50–59, n (%)

12,609 (23.89)

10,595 (23.22)

930 (28.14)

1084 (28.13)

60–69, n (%)

12,625 (23.92)

11,564 (25.35)

289 (8.74)

772 (20.04)

 ≥ 70, n (%)

14,322 (27.14)

13,829 (30.31)

20 (0.61)

473 (12.28)

Age at fracture diagnosis, mean (SD), yearsb

63.58 (12.98)

64.42 (12.66)

49.30 (11.56)

58.07 (12.96)

Time from index date to fracture diagnosis, mean (SD), yearsb

2.55 (2.07)

2.52 (2.07)

2.85 (1.90)

2.78 (2.14)

Sex, Male, n (%)

33,046 (62.61)

28,918 (63.39)

1909 (57.76)

2219 (57.59)

Comorbiditiesc

Diabetes, n (%) E10–E14

33,860 (64.16)

30,061 (65.90)

1501 (45.42)

2298 (59.64)

Hypertension, n (%) I10–I15

47,863 (90.69)

41,189 (90.29)

3141 (95.04)

3533 (91.69)

Cardiovascular, n (%) I20–I25

12,977 (24.59)

11,500 (25.21)

536 (16.22)

941 (24.42)

Cerebrovascular, n (%) I60–I69

7950 (15.06)

7385 (16.19)

191 (5.78)

374 (9.71)

Chronic lung disease, n (%) J40–J47

10,986 (20.82)

9905 (21.71)

494 (14.95)

587 (15.23)

Chronic liver disease, n (%) K70.3, K70.4, K72.1, K73, K74

2239 (4.24)

2022 (4.43)

69 (2.09)

148 (3.84)

Medications at baseline

Steroid

5634 (10.68)

4099 (8.99)

1228 (37.16)

307 (7.97)

Vitamin D and its analog

7848 (14.87)

5733 (12.57)

999 (30.23)

1116 (28.96)

Phosphate binder

23,031 (43.64)

18,046 (39.56)

2449 (74.10)

2536 (65.82)

Anti-osteoporotic agent

1208 (2.29)

1095 (2.40)

48 (1.45)

65 (1.69)

Anti-depressant

7552 (14.31)

6692 (14.67)

309 (9.35)

551 (14.3)

Opioids

2812 (5.33)

2621 (5.75)

73 (2.21)

118 (3.06)

Gabapentinoids

4517 (8.56)

4149 (9.09)

123 (3.72)

245 (6.36)

  1. aP value was based on analysis of variance (ANOVA), otherwise chi-square test.
  2. bAnalyzed in patients with fracture (n = 8995) only.
  3. cComorbidities and medications were observed 1 year before index date; dialysis date or kidney transplant date.
  4. HD hemodialysis, KT kidney transplant, PD peritoneal dialysis, SD standard deviation.
Back to article page